

**PANCREAS  
DISEASE ORIENTED GROUP  
AGENDA  
**OPEN SESSION****

VENUE: ROSSETTI ROOM, DELTA CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 27<sup>TH</sup>, 2013

TIME: 8:00 – 09:00

**CHAIRS: DR. STEVE GALLINGER, DR. DANIEL RENOUF (for DR. MALCOLM MOORE)**

---

08:00	WELCOME AND INTRODUCTION/MEMBERSHIP UPDATE	<b>DR. S. GALLINGER</b>
08:00 – 08:15	OPEN TRIALS	
	<b>PA.6 (ACCORD 24):</b> RANDOMIZED MULTICENTER PHASE III COMPARISON OF ADJUVANT CHEMOTHERAPY WITH GEMCITABINE VERSUS A COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN, IRINOTECAN AND OXALIPLATIN (MFOLFIRINOX) IN PATIENTS WITH RESECTED PANCREATIC ADENOCARCINOMA	<b>DR. A. WEI</b>
08:15 – 08:50	TRIALS/CONCEPTS IN DEVELOPMENT/PROCESS	
	<b>SWOG (S1313):</b> A PHASE IB/II RANDOMIZED STUDY OF MODIFIED FOLFIRINOX + PEGYLATED RECOMBINANT HUMAN HYALURONIDASE (PEGPH20) VERSUS MODIFIED FOLFIRINOX ALONE IN PATIENTS WITH GOOD PERFORMANCE STATUS METASTATIC PANCREATIC ADENOCARCINOMA	<b>DR. S. GALLINGER</b>
	FOLFIRINOX REGISTRY	<b>DR. H. MARGINEAN</b>
	HENT1 BIOMARKER DRIVEN FOLFOX VS GEM TRIAL	<b>DR. M. HO</b>
	PMH CHEMORADS INDUCTION THERAPY PHASE II MAJOR VESSEL INVOLVEMENT	<b>DR. P. SERRANO</b>
	OICR PANCREATIC CANCER GENOMICS ACTIVITY	<b>DR. S. GALLINGER</b>
08:50 – 09:00	INTERGROUP TASK FORCE UPDATE	<b>DR. S. GALLINGER</b>
09:00	CLOSING REMARKS	